Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 3/20 | 0.56 |
| ▸ | STS | P08842 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | F13A1 | P00488 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | TGM1 | P22735 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202414 | 0.91 | STS (0.57) | F10STSF13A1TGM2TGM1 | |
| SCHEMBL6787216 | 0.90 | KMT2A (0.65) | F10GAASMN1; SMN2KMT2AHTT | |
| SCHEMBL6979984 | 0.87 | GAA (0.74) | GAACNR1STSSMN1; SMN2NPSR1 | |
| SCHEMBL5734964 | 0.87 | FNTA (0.52) | F10GAASTSSMN1; SMN2KMT2A | |
| SCHEMBL5734088 | 0.87 | F10 (0.59) | F10GAACNR1SMN1; SMN2NPSR1 | |
| SCHEMBL6982617 | 0.86 | GAA (0.65) | GAACNR1STSNPSR1KMT2A | |
| SCHEMBL6193515 | 0.86 | F10 (0.51) | F10GAASTSSMN1; SMN2KMT2A | |
| SCHEMBL5733446 | 0.85 | F10 (0.57) | F10GAACNR1SMN1; SMN2NPSR1 | |
| SCHEMBL5735808 | 0.85 | F10 (0.57) | F10GAACNR1SMN1; SMN2NPSR1 | |
| SCHEMBL5733444 | 0.85 | F10 (0.57) | F10GAACNR1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | disclosed |
| EP-0844877-B1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ASTRAZENECA AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| EP-1140839-B1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR XA | LILLY CO ELI (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6660739-B1 | Heterocyclic amides as inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-12-09 | — | — | US | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| EP-1140839-A1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6090813-A | Use of oxido-squalene cyclase inhibitors to lower blood cholesterol | ZENECA LIMITED (GB) | 2000-07-18 | — | — | US | disclosed |
| WO-2000039092-A1 | HETEROCYCLIC AMIDES AS INHIBITORS OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0925286-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | disclosed |
| WO-1998006705-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1998-02-19 | — | — | WO | disclosed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | disclosed |